FDA Grants Priority Review to Intravenous Treatment of COVID-19 in Hospitalized Adults

News
Article

FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.

Roche announced on April 4, 2022 that FDA has accepted the company’s supplemental Biologics License Application (sBLA) and has granted Priority Review for Actemra/RoActemra intravenous for the treatment of COVID-19 in hospitalized adults. The treatment is for patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Actemra/RoActemra is currently approved for the treatment of COVID-19 in 16 countries, including the European Union. According to Roche, more than one million hospitalized patients with COVID-19 have been treated with Actemra/RoActemra worldwide. The treatment received Emergency Use Authorization from FDA in June 2021 and prequalification by the World Health Organization (WHO) for patients with severe or critical COVID-19 in February 2022. A decision on FDA approval is expected in the second half of 2022.

Roche is also aiming to establish a comprehensive access approach to improving the availability of its COVID-19 medicines around the world. The company is specifically focusing on providing Actemra/RoActemra via WHO and partners of the Access to COVID-19 Tools Accelerator (ACT-A) Initiative to low and middle-income countries, as well as implementing an international differentiated pricing strategy designed to improve accessibility and affordability worldwide.

“The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalized with COVID-19,” said Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche, in a press release. “More than one million people with severe or critical COVID-19 have already been treated with Actemra/RoActemra worldwide, demonstrating the important role of this medicine in the fight against the pandemic.”

Source: Roche

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes